Inoviq (ASX:IIQ) — Material Events
ASX:IIQ · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
INOVIQ Advances Cancer Diagnostics with $10.2M Raise Amid Rising LossesMedium
INOVIQ reports $3.96M half-year loss, raises A$10.2M to advance cancer diagnostics and therapeutics
18 Feb 2026
·Appendix 4D Half-Year Financial Report
·85
INOVIQ Secures Exclusive Global Licence to Advance Early Ovarian Cancer TestMedium
INOVIQ secures exclusive global licence for ovarian cancer biomarker IP to advance EXO-OC™ test commercialization
26 Sept 2025
·Licence Agreement Announcement
·85
INOVIQ Secures $10.2m to Advance Ovarian Cancer Test and CAR-Exosome TherapyHigh
INOVIQ raises A$10.2m, advances ovarian cancer test and CAR-exosome therapy with new leadership appointments
29 Jan 2026
·Quarterly Business Update and Appendix 4C
·85
INOVIQ Secures $11.5M to Fast-Track Ovarian Cancer Test and TherapeuticsHigh
INOVIQ raises $11.5M to advance ovarian cancer test and therapeutics with Tian An Medicare as cornerstone investor
13 Oct 2025
·Capital Raising
·85
INOVIQ Secures $9.5M to Accelerate Ovarian Cancer Test and CAR-Exosome TherapiesHigh
INOVIQ secures $9.5M funding, advances ovarian cancer test and CAR-exosome therapies with strong preclinical data
29 Oct 2025
·Quarterly Business Update and Appendix 4C
·85
INOVIQ Advances Ovarian Cancer Test and CAR-Exosome Therapeutics with Solid Cash BackingMedium
INOVIQ advances ovarian cancer test clinical study and CAR-exosome therapeutics with strong cash position
28 Apr 2026
·Quarterly Activities Report and Appendix 4C
·85
INOVIQ Raises A$11.5m to Accelerate Cancer Diagnostics and TherapeuticsHigh
INOVIQ launches A$11.5m capital raise to advance exosome cancer diagnostics and therapeutics pipeline
13 Oct 2025
·Capital Raising
·85
INOVIQ’s CAR-NK-Exosomes Slash Tumors by 61.5% in Breast Cancer ModelMedium
INOVIQ’s CAR-NK-Exosome Therapy Shows Promising Breast Cancer Results and Files New Patent
22 Dec 2025
·ASX Announcement
·85
INOVIQ’s CAR-NK-Exosomes Eradicate 90% of Aggressive Breast Cancer Cells In VitroMedium
INOVIQ’s CAR-NK-exosomes show rapid, potent tumor-killing in TNBC cells in vitro
22 Sept 2025
·ASX Announcement
·80
INOVIQ’s CAR-Exosomes Achieve Up to 90% Tumour Kill in Ovarian Cancer CellsMedium
INOVIQ demonstrates strong in vitro tumour killing in ovarian cancer with CAR-exosomes
25 June 2026
·Preclinical Data Announcement
·75
INOVIQ Secures $9.5M Placement, Launches $2M Share Purchase PlanMedium
INOVIQ completes $9.5M placement and launches $2M Share Purchase Plan
17 Oct 2025
·Capital Raising
·75
INOVIQ Flags Sample Quality Issues in EXO-OC Study, Commits to Strategic ReviewMedium
INOVIQ reports sample quality issues in EXO-OC ovarian cancer test study, commits to technical review and dual LDT-IVD commercialisation paths
14 July 2026
·Investor Presentation
·Unexpected
·70
INOVIQ Faces Sample Setback but Advances EXO-OC Algorithm and CAR-Exosome TherapyMedium
INOVIQ reports clinical validation setback for EXO-OC test but advances algorithm and CAR-exosome program with strong cash position
13 July 2026
·Quarterly Activities Report and Appendix 4C
·Unexpected
·65
INOVIQ Links Share Price Rise to Third-Party Research Highlighting Clinical MilestonesMedium
INOVIQ Limited attributes share price rise to third-party research note on clinical milestones, confirms no undisclosed information
17 June 2026
·ASX Price Query Response
·60
No articles in this tier for the last 12 months.
Market Mentions
6
- appeared in market wrap coverage
These are market wrap articles where Inoviq (ASX:IIQ) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 26 (22 June -> 26 June) 2026
27 June 2026
Healthcare Wrap - Week 25 (15 June -> 19 June) 2026
20 June 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026
21 Feb 2026